Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 5/20 | 0.33 |
| ▸ | CDK2 | P24941 | 5/20 | 0.33 |
| ▸ | KDR | P35968 | 5/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CKS1B | P61024 | 1/20 | 0.33 |
| ▸ | SKP1 | P63208 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722934 | 1.00 | STK17B (0.47) | STK17BSTK17AMEN1KMT2ASYK | |
| SCHEMBL20584280 | 1.00 | STK17B (0.47) | STK17BSTK17AMEN1KMT2ASYK | |
| SCHEMBL18495142 | 1.00 | STK17B (0.47) | STK17BSTK17AMEN1KMT2ASYK | |
| SCHEMBL2722846 | 0.91 | STK17B (0.50) | STK17BSTK17AMEN1KMT2ASYK | |
| SCHEMBL29437366 | 0.91 | STK17B (0.50) | STK17BSTK17AMEN1KMT2ASYK | |
| SCHEMBL25949433 | 0.89 | CDK1 (0.35) | STK17BSTK17ASYKPCSK9IGF1R | |
| SCHEMBL15724548 | 0.86 | STK17B (0.52) | STK17BSTK17AMEN1KMT2ASYK | |
| SCHEMBL4549907 | 0.85 | STK17B (0.45) | STK17BSTK17ASYKPCSK9AAK1 | |
| SCHEMBL21967071 | 0.85 | MEN1 (0.38) | STK17BSTK17AMEN1KMT2ACDK1 | |
| SCHEMBL21967070 | 0.85 | MEN1 (0.38) | STK17BSTK17AMEN1KMT2ACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4596051-A2 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | Pharmacosmos Holding A/s (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | PHARMACOSMOS HOLDING A/S (DK) | 2025-04-29 | — | — | US | disclosed |
| EP-2968291-B1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | PHARMACOSMOS HOLDING AS (DK) | 2025-04-16 | — | — | EP | disclosed |
| US-20240109906-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | G1 THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20140142299-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142306-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8691830-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8598186-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8598197-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130237533-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| EP-2632467-A1 | CDK INHIBITORS | G1 Therapeutics, Inc. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012061156-A1 | CDK INHIBITORS | TAVARES FRANCIS X (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237534-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | STK17B 149/4885STK17A 152/4885MEN1 2275/4885 |
| US-20240109906-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | STK17B 149/4885STK17A 152/4885MEN1 2275/4885 |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | STK17B 986/4885STK17A 957/4885MEN1 3437/4885 |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | RB1, CDK4, CDK6 | STK17B 852/4885STK17A 1072/4885MEN1 3291/4885 |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | STK17B 1802/4885STK17A 1642/4885MEN1 455/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | STK17B 1245/4885STK17A 1696/4885MEN1 3666/4885 |
| US-20140142306-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | STK17B 149/4885STK17A 152/4885MEN1 2275/4885 |
| US-20130237533-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | STK17B 149/4885STK17A 152/4885MEN1 2275/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | STK17B 676/4885STK17A 835/4885MEN1 1943/4885 |
| US-20140142299-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | STK17B 149/4885STK17A 152/4885MEN1 2275/4885 |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | RB1, CDK4, CDKN1A | STK17B 986/4885STK17A 957/4885MEN1 3437/4885 |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | STK17B 1245/4885STK17A 1696/4885MEN1 3666/4885 |
| US-20130237544-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | STK17B 149/4885STK17A 152/4885MEN1 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.